A 48-WEEK (24-WEEK BASELINE FOLLOWED BY A 24-WEEK TREATMENT) PHASE II PILOT STUDY OF THE TOLERABILITY AND EFFECT/EFFICACY OF SUBCUTANEOUSLY ADMINISTERED INSULIN-LIKE GROWTH FACTOR-1 (RHIGF) (CEP-151) IN MULTIPLE SCLEROSIS (MS) PATIENTS: